Invitrogen™ Aprutumab Recombinant Monoclonal Antibody

Aprutumab is a biosimilar that targets FGFR2. FGFR2 is a member of the fibroblast growth factor receptor family. It is a tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a central role in the regulation of cell proliferation, differentiation, migration, apoptosis, and embryonic development. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene.